Cargando…
The value of serum HE4 and CA125 levels for monitoring the recurrence and risk stratification of endometrial endometrioid carcinoma
To evaluate the role of serum human epididymis secretory protein 4 (HE4) and carbohydrate antigen 125 (CA125) levels for predicting and monitoring the recurrence of endometrial endometrioid carcinoma (EEC) and assessing preoperative risk stratification in EEC patients. A total of 434 EEC patients we...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373916/ https://www.ncbi.nlm.nih.gov/pubmed/37519747 http://dx.doi.org/10.1016/j.heliyon.2023.e18016 |
_version_ | 1785078662324813824 |
---|---|
author | Gong, Sainan Quan, Quan Meng, Yu Wu, Jingxian Yang, Shuang Hu, Jiaming Mu, Xiaoling |
author_facet | Gong, Sainan Quan, Quan Meng, Yu Wu, Jingxian Yang, Shuang Hu, Jiaming Mu, Xiaoling |
author_sort | Gong, Sainan |
collection | PubMed |
description | To evaluate the role of serum human epididymis secretory protein 4 (HE4) and carbohydrate antigen 125 (CA125) levels for predicting and monitoring the recurrence of endometrial endometrioid carcinoma (EEC) and assessing preoperative risk stratification in EEC patients. A total of 434 EEC patients were selected for this retrospective study between May 2011 and August 2018. Serum HE4 and CA125 levels were analyzed before the initial treatment, at the first postoperative follow-up, and at recurrence or the last follow-up. Patients were risk stratified according to the European Society for Medical Oncology (ESMO), European Society for Radiotherapy & Oncology (ESTRO) and European Society of Gynaecological Oncology (ESGO) guideline. We compared the ability of these biomarkers for prediction and monitoring by performing receiver operating characteristic curve analysis and identified optimal cut-off values by determining the Youden index. Kaplan-Meier analyses were also performed to determine prognostic value. Preoperative serum HE4 was identified as a significant predictor for the recurrence of EEC (p = 0.014). Preoperative serum HE4 and CA125 levels were related to depth of myometrial invasion, lymph node status and FIGO stage. Serum HE4 and CA125 levels were both statistically significant markers for monitoring the recurrence of EEC (P = 0.000 for each biomarker). When combined, the two markers showed higher levels of sensitivity and specificity. The two biomarkers were also significant biomarkers for evaluating the risk stratification of patients undergoing lymphadenectomy (P = 0.000 for each biomarker). For premenopausal stage I patients, preoperative serum HE4 and CA125 levels were significant predictors of the need for ovarian preservation (P = 0.000 and P = 0.002, respectively). For premenopausal patients with stage I intramucosal differentiation, preoperative serum levels of HE4 were significant predictors for fertility preservation (P = 0.024). Preoperative serum HE4 level can be used to predict the recurrence of EEC. Postoperative serum HE4 and CA125 levels can be used to monitor the recurrence of EEC and are more sensitive when combined. Preoperative serum levels of CA125 and HE4 levels are of significant value for risk stratification in EEC patients. |
format | Online Article Text |
id | pubmed-10373916 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-103739162023-07-28 The value of serum HE4 and CA125 levels for monitoring the recurrence and risk stratification of endometrial endometrioid carcinoma Gong, Sainan Quan, Quan Meng, Yu Wu, Jingxian Yang, Shuang Hu, Jiaming Mu, Xiaoling Heliyon Research Article To evaluate the role of serum human epididymis secretory protein 4 (HE4) and carbohydrate antigen 125 (CA125) levels for predicting and monitoring the recurrence of endometrial endometrioid carcinoma (EEC) and assessing preoperative risk stratification in EEC patients. A total of 434 EEC patients were selected for this retrospective study between May 2011 and August 2018. Serum HE4 and CA125 levels were analyzed before the initial treatment, at the first postoperative follow-up, and at recurrence or the last follow-up. Patients were risk stratified according to the European Society for Medical Oncology (ESMO), European Society for Radiotherapy & Oncology (ESTRO) and European Society of Gynaecological Oncology (ESGO) guideline. We compared the ability of these biomarkers for prediction and monitoring by performing receiver operating characteristic curve analysis and identified optimal cut-off values by determining the Youden index. Kaplan-Meier analyses were also performed to determine prognostic value. Preoperative serum HE4 was identified as a significant predictor for the recurrence of EEC (p = 0.014). Preoperative serum HE4 and CA125 levels were related to depth of myometrial invasion, lymph node status and FIGO stage. Serum HE4 and CA125 levels were both statistically significant markers for monitoring the recurrence of EEC (P = 0.000 for each biomarker). When combined, the two markers showed higher levels of sensitivity and specificity. The two biomarkers were also significant biomarkers for evaluating the risk stratification of patients undergoing lymphadenectomy (P = 0.000 for each biomarker). For premenopausal stage I patients, preoperative serum HE4 and CA125 levels were significant predictors of the need for ovarian preservation (P = 0.000 and P = 0.002, respectively). For premenopausal patients with stage I intramucosal differentiation, preoperative serum levels of HE4 were significant predictors for fertility preservation (P = 0.024). Preoperative serum HE4 level can be used to predict the recurrence of EEC. Postoperative serum HE4 and CA125 levels can be used to monitor the recurrence of EEC and are more sensitive when combined. Preoperative serum levels of CA125 and HE4 levels are of significant value for risk stratification in EEC patients. Elsevier 2023-07-08 /pmc/articles/PMC10373916/ /pubmed/37519747 http://dx.doi.org/10.1016/j.heliyon.2023.e18016 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Article Gong, Sainan Quan, Quan Meng, Yu Wu, Jingxian Yang, Shuang Hu, Jiaming Mu, Xiaoling The value of serum HE4 and CA125 levels for monitoring the recurrence and risk stratification of endometrial endometrioid carcinoma |
title | The value of serum HE4 and CA125 levels for monitoring the recurrence and risk stratification of endometrial endometrioid carcinoma |
title_full | The value of serum HE4 and CA125 levels for monitoring the recurrence and risk stratification of endometrial endometrioid carcinoma |
title_fullStr | The value of serum HE4 and CA125 levels for monitoring the recurrence and risk stratification of endometrial endometrioid carcinoma |
title_full_unstemmed | The value of serum HE4 and CA125 levels for monitoring the recurrence and risk stratification of endometrial endometrioid carcinoma |
title_short | The value of serum HE4 and CA125 levels for monitoring the recurrence and risk stratification of endometrial endometrioid carcinoma |
title_sort | value of serum he4 and ca125 levels for monitoring the recurrence and risk stratification of endometrial endometrioid carcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373916/ https://www.ncbi.nlm.nih.gov/pubmed/37519747 http://dx.doi.org/10.1016/j.heliyon.2023.e18016 |
work_keys_str_mv | AT gongsainan thevalueofserumhe4andca125levelsformonitoringtherecurrenceandriskstratificationofendometrialendometrioidcarcinoma AT quanquan thevalueofserumhe4andca125levelsformonitoringtherecurrenceandriskstratificationofendometrialendometrioidcarcinoma AT mengyu thevalueofserumhe4andca125levelsformonitoringtherecurrenceandriskstratificationofendometrialendometrioidcarcinoma AT wujingxian thevalueofserumhe4andca125levelsformonitoringtherecurrenceandriskstratificationofendometrialendometrioidcarcinoma AT yangshuang thevalueofserumhe4andca125levelsformonitoringtherecurrenceandriskstratificationofendometrialendometrioidcarcinoma AT hujiaming thevalueofserumhe4andca125levelsformonitoringtherecurrenceandriskstratificationofendometrialendometrioidcarcinoma AT muxiaoling thevalueofserumhe4andca125levelsformonitoringtherecurrenceandriskstratificationofendometrialendometrioidcarcinoma AT gongsainan valueofserumhe4andca125levelsformonitoringtherecurrenceandriskstratificationofendometrialendometrioidcarcinoma AT quanquan valueofserumhe4andca125levelsformonitoringtherecurrenceandriskstratificationofendometrialendometrioidcarcinoma AT mengyu valueofserumhe4andca125levelsformonitoringtherecurrenceandriskstratificationofendometrialendometrioidcarcinoma AT wujingxian valueofserumhe4andca125levelsformonitoringtherecurrenceandriskstratificationofendometrialendometrioidcarcinoma AT yangshuang valueofserumhe4andca125levelsformonitoringtherecurrenceandriskstratificationofendometrialendometrioidcarcinoma AT hujiaming valueofserumhe4andca125levelsformonitoringtherecurrenceandriskstratificationofendometrialendometrioidcarcinoma AT muxiaoling valueofserumhe4andca125levelsformonitoringtherecurrenceandriskstratificationofendometrialendometrioidcarcinoma |